2,000-year-old steel acupuncture needles unearthed in China's Jiangxi province
Steel acupuncture needles inside a jade tube discovered in the famed tomb of the Marquis of Haihun in Nanchang, Jiangxi province. - China Daily/ANN
"At least five needle-like objects were visible in the tube's cross-section," said Yang Jun, leader of the excavation team at the Marquis of Haihun's tomb in Jiangxi.
The delicate needles date back over 2,000 years. They were discovered in a jade tube inside a gold-foiled lacquer box and were crafted with steelworking techniques far ahead of their time. Centuries underground have left them corroded and broken, requiring careful analysis to confirm their purpose.
Steel needles and a jade tube discovered in the famed tomb of the Marquis of Haihun. - China Daily/ANN
Each needle measures 0.3 to 0.5mm in diameter. Yang noted that they were likely wrapped in cloth prior to being placed in the jade tube, a practice that ensured hygiene and safe handling.
Gu Man, an expert from the China Academy of Chinese Medical Sciences, said the needles are believed to be the earliest steel medical acupuncture needles discovered in China to date, serving as crucial evidence for the history of steel metallurgy and ancient Chinese medicine during the Western Han Dynasty (206 BC-AD 24). - China Daily/ANN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ — Brii Biosciences Limited ('Brii Bio,' stock code: a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ('Joincare Group'). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: 'The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections.' Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, 'The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options.' About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ('Brii Bio', stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
The Star
a day ago
- The Star
Kenya launches second phase of China-sponsored youth coding initiative
NAIROBI, July 3 (Xinhua) -- Kenya on Thursday launched the second phase of a youth coding initiative supported by CODEMAO, a Chinese online education platform, in partnership with the United Nations Educational, Scientific and Cultural Organization (UNESCO). The launch event marked the beginning of the initiative's second phase, which will run from 2025 to 2030. The program aims to enhance digital literacy among adolescent learners across the country. Julius Bitok, principal secretary in the Ministry of Education, said Kenya is the first country in Africa to launch the second phase of the UNESCO-CODEMAO coding initiative for youth, as part of its efforts to build a digital, interconnected and inclusive future. "To prepare our youth for the jobs and challenges of tomorrow, we must invest in digital skills today. We support initiatives that foster innovation, digital literacy, and 21st-century competencies," Bitok said. Kenya was among the African countries, including Namibia and the Republic of the Congo, that implemented the first phase of the UNESCO-CODEMAO youth coding initiative from 2022 to 2024, aimed at enhancing coding and artificial intelligence (AI) skills among students and teachers. During the first phase, junior secondary school students and their teachers received devices and hands-on training in various aspects of coding and AI, culminating in the award of certificates of recognition. Four outstanding pupils and one teacher will participate in a week-long study tour to the southeastern Chinese city of Shenzhen from July 9 to 16, where they will visit technology companies and engage with Chinese culture. Activities planned for the second phase include online training and mentorship designed to strengthen the coding and AI capabilities of students and teachers. UNESCO's Regional Director for Eastern Africa Louise Haxthausen said the partnership with CODEMAO has played a key role in introducing Kenyan learners to digital tools, including AI. During the second phase, students will be provided with tablets and both theoretical and practical lessons to help them harness coding and AI for innovation and leadership in the technology sector. CODEMAO Chief Executive Officer Tianchi Li said in a video message that the organization is committed to supporting Kenya's digital transformation by investing in infrastructure, training, mentorship, and exposing young learners to cutting-edge technologies.
The Sun
2 days ago
- The Sun
Japan plans ‘world first' deep-sea mineral extraction
TOKYO: Japan will from January attempt to extract rare earth minerals from the ocean floor in the deepest trial of its kind, the director of a government innovation programme said Thursday. Earlier this week the country pledged to work with the United States, India and Australia to ensure a stable supply of critical minerals, as concern grows over China's dominance in resources vital to new technologies. Rare earths -- 17 metals difficult to extract from the Earth's crust -- are used in everything from electric vehicles to hard drives, wind turbines and missiles. China accounts for almost two-thirds of rare earth mining production and 92 percent of global refined output, according to the International Energy Agency. A Japanese deep-sea scientific drilling boat called the Chikyu will from January conduct a 'test cruise' to retrieve ocean floor sediments that contain rare earth elements, said Shoichi Ishii, director of Japan's Cross-ministerial Strategic Innovation Promotion Programme. 'The test to retrieve the sediments from 5,500 metres (3.4 miles) water depth is the first in the world,' he told AFP. 'Our goal... of this cruise is to test the function of all mining equipment,' so the amount of sediment extracted 'doesn't matter at all', Ishii added. The Chikyu will drill in Japanese economic waters around the remote island of Minami Torishima in the Pacific -- the easternmost point of Japan, also used as a military base. Japan's Nikkei business daily reported that the mission aims to extract 35 tonnes of mud from the sea floor over around three weeks. Each tonne is expected to contain around two kilograms (4.4 pounds) of rare earth minerals, which are often used to make magnets that are essential in modern electronics. Deep-sea mining has become a geopolitical flashpoint, with anxiety growing over a push by US President Donald Trump to fast-track the practice in international waters. Beijing has since April required licences to export rare earths from China, a move seen as retaliation for US curbs on the import of Chinese goods. Environmental campaigners warn that deep-sea mining threatens marine ecosystems and will disrupt the sea floor. The International Seabed Authority, which has jurisdiction over the ocean floor outside national waters, is meeting later this month to discuss a global code to regulate mining in the ocean depths. – AFP
